Our Current Portfolio at a Glance
Our EXIS™️ platform drives a portfolio of fully human antibody therapeutics across multiple disease areas. We are currently advancing candidates in Immunology & Inflammation, Obesity & Metabolic Disorders, and Oncology, with plans to expand into new indications.
Programs& Their Components
Target CredentialingTar CredTarBiology + Development + Strategy
EXIS™️+ Antigen AIEXIS & AIEXISHit Discovery + Optimization
Lead OptimizationLead Opt. LeadCell Testing + Multispecific Design
Candidate SelectionCan. Sel.Sel.Animal Testing + early CMC
IND-EnablingINDINDFull PK/PD, Safety + GMP / CMC
Phase 1Ph. 1P1
Obesity
Mono GIPR*
Tar
EXIS
Lead
Sel.
ClinicIND
P1
GIPR*/
GLP-1
Tar
EXIS
Lead
Sel.
ClinicIND
P1
GIPR*/
GLP-1/
Glucagon
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Activin
RIIB
Tar
EXIS
Lead
Sel.
ClinicIND
P1
GPR 75
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Activin / GLP-1 bispecific
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Immunology and Inflammation
TL1A/IL-23
Tar
EXIS
Lead
Sel.
ClinicIND
P1
IL-23
Tar
EXIS
Lead
Sel.
ClinicIND
P1
OX40
Tar
EXIS
Lead
Sel.
ClinicIND
P1
a4B7
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Oncology
CD3
Tar
EXIS
Lead
Sel.
ClinicIND
P1
SLC7A11
Tar
EXIS
Lead
Sel.
ClinicIND
P1
TCR-mediated targets
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Veterinarian
Canine NGF
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Canine IL-31
Tar
EXIS
Lead
Sel.
ClinicIND
P1
— Clinically-Validates
— Novel Targets
* — Antagonist